Evidence map›Paper›PMID 39530293›Full record

ReviewTherapeutic advances in cardiovascular disease

What's new in cardiac amyloidosis? Pharmacological treatment, physical activity, and care of patients with transthyretin cardiac amyloidosis.

Ezequiel J Zaidel, Sol C Song, Juan J Sterba, Agustina Piccinato, María Candelaria Ramos, Silvina L Cacia

Abstract readReview
In one paragraph

Review in Therapeutic advances in cardiovascular disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ezequiel J ZaidelCardiovascular Pharmacology Research Group, Department of Pharmacology and Toxicology, Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina.
Sol C SongDepartment of Pharmacology and Toxicology, Faculty of Medicine, University of Buenos Aires, Paraguay 2110, 15th Floor, Buenos Aires C1121A6B, Argentina.ORCID 0009-0004-5525-6908
Juan J SterbaCardiovascular Pharmacology Research Group, Department of Pharmacology and Toxicology, Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina.ORCID 0009-0000-1241-2502
Agustina PiccinatoCardiovascular Pharmacology Research Group, Department of Pharmacology and Toxicology, Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina.
María Candelaria RamosCardiovascular Pharmacology Research Group, Department of Pharmacology and Toxicology, Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina.
Silvina L CaciaCardiovascular Pharmacology Research Group, Department of Pharmacology and Toxicology, Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Awareness, proper diagnosis and treatment of cardiac amyloidosis have increased, but there are still several unmet needs that have to be addressed for the optimal care of the disease. In this comprehensive review, we describe current and future treatments for both hereditary and wild-type TTR cardiac amyloidosis and also review lifestyle, including current challenges and opportunities for specific dietary concerns and exercise sports for these patients.

Indexed as

Amyloid Neuropathies, FamilialCardiomyopathiesExerciseCardiovascular AgentsExercise TherapyGenetic Predisposition to DiseaseHumansPrealbuminRisk Reduction BehaviorTreatment OutcomeCardiovascular AgentsPrealbuminTTR protein, humancardiac amyloidosiscardiomyopathydisease-modifying agentsheart failuresmall interfering RNA

Identifiers

PMID39530293
PMCPMC11558729

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.